Publisher: MarketsandMarkets
# of Pages: 177
Rating:
1 User License $4,950
Publication Date: October, 2021
Price: $4,950 / User License
Buy Now
RPT50247
LIC503
1 User $4,950
1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 24
1.3 MARKET SCOPE 25
FIGURE 1 VASCULAR CLOSURE DEVICES MARKET SEGMENTATION 25
1.3.1 YEARS CONSIDERED FOR THE STUDY 25
1.4 CURRENCY 26
1.5 STAKEHOLDERS 26
1.6 SUMMARY OF CHANGES 26
2 RESEARCH METHODOLOGY 27
2.1 RESEARCH DATA 27
FIGURE 2 RESEARCH DESIGN 27
2.2 SECONDARY DATA 28
2.2.1 SECONDARY SOURCES 29
2.3 PRIMARY DATA 30
FIGURE 3 PRIMARY SOURCES 30
2.3.1 KEY DATA FROM PRIMARY SOURCES 31
2.3.2 KEY INDUSTRY INSIGHTS 32
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 33
2.4 MARKET SIZE ESTIMATION 33
FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 34
2.4.1 GROWTH FORECAST 35
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 35
FIGURE 7 TOP-DOWN APPROACH 36
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 37
FIGURE 8 DATA TRIANGULATION METHODOLOGY 37
2.6 MARKET SHARE ANALYSIS 38
2.7 ASSUMPTIONS FOR THE STUDY 38
2.7.1 COVID-19-SPECIFIC ASSUMPTIONS 39
2.8 LIMITATIONS 39
2.9 RISK ASSESSMENT 40
2.10 COVID-19 ECONOMIC ASSESSMENT 40
2.11 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 41
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY 41
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 42
3 EXECUTIVE SUMMARY 43
FIGURE 11 VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 43
FIGURE 12 VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2021 VS. 2026 (USD MILLION) 44
FIGURE 13 VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2021 VS. 2026 (USD MILLION) 44
FIGURE 14 VASCULAR CLOSURE DEVICES MARKET, BY REGION,
2021 VS. 2026 (USD MILLION) 45
4 PREMIUM INSIGHTS 46
4.1 VASCULAR CLOSURE DEVICES MARKET OVERVIEW 46
FIGURE 15 LARGE NUMBER OF APPROVALS FOR VASCULAR CLOSURE DEVICES TO DRIVE MARKET GROWTH 46
4.2 VASCULAR CLOSURE DEVICES MARKET, BY TYPE (2021–2026) 47
FIGURE 16 PASSIVE APPROXIMATORS SEGMENT TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 47
4.3 NORTH AMERICA: VASCULAR CLOSURE DEVICES MARKET,
BY TYPE AND COUNTRY (2020) 48
FIGURE 17 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN VASCULAR CLOSURE DEVICES MARKET IN 2020 48
4.4 VASCULAR CLOSURE DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 49
FIGURE 18 US TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 49
5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
FIGURE 19 VASCULAR CLOSURE DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50
5.2 MARKET DYNAMICS 51
5.2.1 DRIVERS 51
5.2.1.1 Growing approvals of vascular closure devices 51
TABLE 1 APPROVALS OF VASCULAR CLOSURE DEVICES 51
5.2.1.2 High prevalence of cardiovascular diseases 51
5.2.1.3 Increasing prevalence of obesity 52
5.2.1.4 Increasing focus of market players on large-bore vascular closure devices 52
5.2.1.5 Growing geriatric population 52
5.2.1.6 Favorable reimbursement scenario for interventional radiology procedures 53
TABLE 2 REIMBURSEMENTS FOR INTERVENTIONAL RADIOLOGY PROCEDURES IN THE US 53
5.2.1.7 Rising focus on effective blood loss management in patients during surgeries 54
5.2.1.8 Increasing investments, funds, and grants for research on vascular devices 54
5.2.2 RESTRAINTS 54
5.2.2.1 Increasing preference for interventional procedures using radial artery access 54
5.2.2.2 High cost of vascular closure devices 55
5.2.2.3 Product recalls and failures 55
TABLE 3 RECENT RECALLS OF VASCULAR CLOSURE DEVICES 55
5.2.3 OPPORTUNITIES 56
5.2.3.1 Emerging markets providing growth opportunities for market players 56
5.2.3.2 Growth in the number of hospitals & surgical centers 56
5.2.4 CHALLENGES 56
5.2.4.1 Need for highly skilled professionals 56
5.2.4.2 Risks associated with vascular closure devices 57
5.2.4.3 Stringent regulatory frameworks 57
5.3 COVID-19 IMPACT ON THE VASCULAR CLOSURE DEVICES MARKET 58
6 VASCULAR CLOSURE DEVICES MARKET, BY TYPE 60
6.1 INTRODUCTION 61
TABLE 4 VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 61
TABLE 5 VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 61
6.2 PASSIVE APPROXIMATORS 62
TABLE 6 PASSIVE APPROXIMATORS MARKET, BY TYPE, 2017–2020 (USD MILLION) 62
TABLE 7 PASSIVE APPROXIMATORS MARKET, BY TYPE, 2021–2026 (USD MILLION) 62
TABLE 8 PASSIVE APPROXIMATORS MARKET, BY REGION, 2017–2020 (USD MILLION) 63
TABLE 9 PASSIVE APPROXIMATORS MARKET, BY REGION, 2021–2026 (USD MILLION) 63
6.2.1 COLLAGEN PLUGS 63
6.2.1.1 Growing number of approvals for collagen-based vascular closure devices to drive market growth during the forecast period 63
TABLE 10 COLLAGEN PLUGS MARKET, BY REGION, 2017–2020 (USD MILLION) 64
TABLE 11 COLLAGEN PLUGS MARKET, BY REGION, 2021–2026 (USD MILLION) 64
6.2.2 SEALANT OR GEL-BASED DEVICES 65
6.2.2.1 Sealant or gel-based devices to register the highest growth rate during the forecast period 65
TABLE 12 SEALANT OR GEL-BASED DEVICES MARKET, BY REGION,
2017–2020 (USD MILLION) 65
TABLE 13 SEALANT OR GEL-BASED DEVICES MARKET, BY REGION,
2021–2026 (USD MILLION) 66
6.2.3 COMPRESSION ASSIST DEVICES 66
6.2.3.1 Compression assist devices do not leave behind any foreign body in the tissue artery—a major advantage of these devices 66
TABLE 14 COMPRESSION ASSIST DEVICES MARKET, BY REGION,
2017–2020 (USD MILLION) 66
TABLE 15 COMPRESSION ASSIST DEVICES MARKET, BY REGION,
2021–2026 (USD MILLION) 67
6.3 ACTIVE APPROXIMATORS 67
TABLE 16 ACTIVE APPROXIMATORS MARKET, BY TYPE, 2017–2020 (USD MILLION) 67
TABLE 17 ACTIVE APPROXIMATORS MARKET, BY TYPE, 2021–2026 (USD MILLION) 68
TABLE 18 ACTIVE APPROXIMATORS MARKET, BY REGION, 2017–2020 (USD MILLION) 68
TABLE 19 ACTIVE APPROXIMATORS MARKET, BY REGION, 2021–2026 (USD MILLION) 68
6.3.1 SUTURE-BASED DEVICES 69
6.3.1.1 Increasing applications of suture-based devices to
favor market growth 69
TABLE 20 SUTURE-BASED ACTIVE APPROXIMATORS MARKET, BY REGION,
2017–2020 (USD MILLION) 69
TABLE 21 SUTURE-BASED ACTIVE APPROXIMATORS MARKET, BY REGION,
2021–2026 (USD MILLION) 70
6.3.2 CLIP-BASED DEVICES 70
6.3.2.1 Growing innovation in the field of clip-based devices to aid market growth 70
TABLE 22 CLIP-BASED ACTIVE APPROXIMATORS MARKET, BY REGION,
2017–2020 (USD MILLION) 71
TABLE 23 CLIP-BASED ACTIVE APPROXIMATORS MARKET, BY REGION,
2021–2026 (USD MILLION) 71
6.4 EXTERNAL HEMOSTATIC DEVICES 71
6.4.1 RISING ADOPTION OF MINIMALLY INVASIVE THERAPEUTIC PROCEDURES TO DRIVE MARKET GROWTH 71
TABLE 24 EXTERNAL HEMOSTATIC DEVICES MARKET, BY REGION,
2017–2020 (USD MILLION) 72
TABLE 25 EXTERNAL HEMOSTATIC DEVICES MARKET, BY REGION,
2021–2026 (USD MILLION) 72
7 VASCULAR CLOSURE DEVICES MARKET, BY ACCESS 73
7.1 INTRODUCTION 74
TABLE 26 VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2017–2020 (USD MILLION) 74
TABLE 27 VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2021–2026 (USD MILLION) 74
7.2 FEMORAL ACCESS 75
7.2.1 ADVANTAGES ASSOCIATED WITH FEMORAL ACCESS, SUCH AS GREATER COMFORT LEVEL FOR PATIENTS AND REDUCED COST OF HOSPITALIZATION, TO DRIVE MARKET GROWTH 75
TABLE 28 FEMORAL ACCESS: RESEARCH STUDIES 75
TABLE 29 FEMORAL ACCESS VASCULAR CLOSURE DEVICES MARKET, BY REGION, 2017–2020 (USD MILLION) 76
TABLE 30 FEMORAL ACCESS VASCULAR CLOSURE DEVICES MARKET, BY REGION, 2021–2026 (USD MILLION) 76
7.3 RADIAL ACCESS 77
7.3.1 TRANSRADIAL APPROACH REDUCES VASCULAR COMPLICATIONS COMPARED TO THE FEMORAL ARTERY ACCESS APPROACH—A KEY FACTOR DRIVING MARKET GROWTH 77
TABLE 31 RADIAL ACCESS VASCULAR CLOSURE DEVICES MARKET, BY REGION,
2017–2020 (USD MILLION) 77
TABLE 32 RADIAL ACCESS VASCULAR CLOSURE DEVICES MARKET, BY REGION,
2021–2026 (USD MILLION) 78
8 VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE 79
8.1 INTRODUCTION 80
TABLE 33 VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2017–2020 (USD MILLION) 80
TABLE 34 VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2021–2026 (USD MILLION) 80
8.2 INTERVENTIONAL CARDIOLOGY 81
8.2.1 ASSOCIATED BENEFITS OF INTERVENTIONAL CARDIOLOGY PROCEDURES, SUCH AS REDUCED SCARRING AND LESS PAIN, TO DRIVE MARKET GROWTH 81
TABLE 35 VASCULAR CLOSURE DEVICES MARKET FOR INTERVENTIONAL CARDIOLOGY PROCEDURES, BY REGION, 2017–2020 (USD MILLION) 82
TABLE 36 VASCULAR CLOSURE DEVICES MARKET FOR INTERVENTIONAL CARDIOLOGY PROCEDURES, BY REGION, 2021–2026 (USD MILLION) 82
8.3 INTERVENTIONAL RADIOLOGY/VASCULAR SURGERY 83
8.3.1 GROWTH IN THE PREVALENCE OF PAD IS INCREASING THE DEMAND FOR ENDOVASCULAR INTERVENTIONAL PROCEDURES 83
TABLE 37 VASCULAR CLOSURE DEVICES MARKET FOR INTERVENTIONAL RADIOLOGY/VASCULAR SURGERY PROCEDURES, BY REGION,
2017–2020 (USD MILLION) 83
TABLE 38 VASCULAR CLOSURE DEVICES MARKET FOR INTERVENTIONAL RADIOLOGY/VASCULAR SURGERY PROCEDURES, BY REGION,
2021–2026 (USD MILLION) 84
9 VASCULAR CLOSURE DEVICES MARKET, BY REGION 85
9.1 INTRODUCTION 86
TABLE 39 VASCULAR CLOSURE DEVICES MARKET, BY REGION,
2017–2020 (USD MILLION) 86
TABLE 40 VASCULAR CLOSURE DEVICES MARKET, BY REGION,
2021–2026 (USD MILLION) 86
9.2 NORTH AMERICA 87
FIGURE 20 NORTH AMERICA: VASCULAR CLOSURE DEVICES MARKET SNAPSHOT 88
TABLE 41 NORTH AMERICA: VASCULAR CLOSURE DEVICES MARKET, BY COUNTRY, 2017–2020 (USD MILLION) 88
TABLE 42 NORTH AMERICA: VASCULAR CLOSURE DEVICES MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 89
TABLE 43 NORTH AMERICA: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 89
TABLE 44 NORTH AMERICA: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 89
TABLE 45 NORTH AMERICA: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 90
TABLE 46 NORTH AMERICA: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 90
TABLE 47 NORTH AMERICA: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 90
TABLE 48 NORTH AMERICA: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 91
TABLE 49 NORTH AMERICA: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS, 2017–2020 (USD MILLION) 91
TABLE 50 NORTH AMERICA: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS, 2021–2026 (USD MILLION) 91
TABLE 51 NORTH AMERICA: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE, 2017–2020 (USD MILLION) 92
TABLE 52 NORTH AMERICA: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE, 2021–2026 (USD MILLION) 92
9.2.1 US 92
9.2.1.1 The US dominates the North American vascular closure
devices market 92
TABLE 53 REIMBURSEMENTS FOR INTERVENTIONAL CARDIOLOGY PROCEDURES, 2020 93
TABLE 54 US: KEY MACROINDICATORS 94
TABLE 55 US: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 94
TABLE 56 US: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 95
TABLE 57 US: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 95
TABLE 58 US: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 95
TABLE 59 US: ACTIVE APPROXIMATORS MARKET, BY TYPE, 2017–2020 (USD MILLION) 96
TABLE 60 US: ACTIVE APPROXIMATORS MARKET, BY TYPE, 2021–2026 (USD MILLION) 96
TABLE 61 US: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2017–2020 (USD MILLION) 96
TABLE 62 US: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2021–2026 (USD MILLION) 97
TABLE 63 US: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2017–2020 (USD MILLION) 97
TABLE 64 US: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2021–2026 (USD MILLION) 97
9.2.2 CANADA 98
9.2.2.1 Rising prevalence of target diseases to drive market growth 98
TABLE 65 CANADA: KEY MACROINDICATORS 98
TABLE 66 CANADA: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 99
TABLE 67 CANADA: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 99
TABLE 68 CANADA: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 99
TABLE 69 CANADA: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 100
TABLE 70 CANADA: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 100
TABLE 71 CANADA: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 100
TABLE 72 CANADA: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2017–2020 (USD MILLION) 101
TABLE 73 CANADA: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2021–2026 (USD MILLION) 101
TABLE 74 CANADA: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2017–2020 (USD MILLION) 101
TABLE 75 CANADA: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2021–2026 (USD MILLION) 102
9.3 EUROPE 102
TABLE 76 NUMBER OF SURGICAL PROCEDURES PER 100,000 POPULATION,
BY COUNTRY, 2018 102
TABLE 77 EUROPE: VASCULAR CLOSURE DEVICES MARKET, BY COUNTRY,
2017–2020 (USD MILLION) 103
TABLE 78 EUROPE: VASCULAR CLOSURE DEVICES MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 103
TABLE 79 EUROPE: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 103
TABLE 80 EUROPE: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 104
TABLE 81 EUROPE: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 104
TABLE 82 EUROPE: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 104
TABLE 83 EUROPE: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 105
TABLE 84 EUROPE: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 105
TABLE 85 EUROPE: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2017–2020 (USD MILLION) 105
TABLE 86 EUROPE: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2021–2026 (USD MILLION) 106
TABLE 87 EUROPE: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2017–2020 (USD MILLION) 106
TABLE 88 EUROPE: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2021–2026 (USD MILLION) 106
9.3.1 E-3 107
9.3.1.1 Increase in number of radial procedures to boost the market demand 107
TABLE 89 GERMANY: KEY MACROINDICATORS 107
TABLE 90 UK: KEY MACROINDICATORS 108
TABLE 91 FRANCE: KEY MACROINDICATORS 109
TABLE 92 E-3: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 110
TABLE 93 E-3: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 110
TABLE 94 E-3: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 110
TABLE 95 E-3: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 111
TABLE 96 E-3: ACTIVE APPROXIMATORS MARKET, BY TYPE, 2017–2020 (USD MILLION) 111
TABLE 97 E-3: ACTIVE APPROXIMATORS MARKET, BY TYPE, 2021–2026 (USD MILLION) 111
TABLE 98 E-3: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2017–2020 (USD MILLION) 112
TABLE 99 E-3: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2021–2026 (USD MILLION) 112
TABLE 100 E-3: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2017–2020 (USD MILLION) 112
TABLE 101 E-3: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2021–2026 (USD MILLION) 113
9.3.2 REST OF EUROPE 113
TABLE 102 ROE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2018 (% OF GDP) 114
TABLE 103 ROE: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 114
TABLE 104 ROE: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 115
TABLE 105 ROE: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 115
TABLE 106 ROE: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 115
TABLE 107 ROE: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 116
TABLE 108 ROE: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 116
TABLE 109 ROE: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2017–2020 (USD MILLION) 116
TABLE 110 ROE: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2021–2026 (USD MILLION) 117
TABLE 111 ROE: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2017–2020 (USD MILLION) 117
TABLE 112 ROE: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2021–2026 (USD MILLION) 117
9.4 ASIA PACIFIC 118
9.4.1 INCREASING HEALTH EXPENDITURE TO DRIVE MARKET GROWTH IN APAC 118
FIGURE 21 ASIA PACIFIC: VASCULAR CLOSURE DEVICES MARKET SNAPSHOT 119
TABLE 113 CHINA: KEY MACROINDICATORS 120
TABLE 114 JAPAN: KEY MACROINDICATORS 121
TABLE 115 INDIA: KEY INDICATORS 122
TABLE 116 ASIA PACIFIC: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 123
TABLE 117 ASIA PACIFIC: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 123
TABLE 118 ASIA PACIFIC: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 123
TABLE 119 ASIA PACIFIC: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 124
TABLE 120 ASIA PACIFIC: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 124
TABLE 121 ASIA PACIFIC: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 124
TABLE 122 ASIA PACIFIC: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2017–2020 (USD MILLION) 125
TABLE 123 ASIA PACIFIC: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2021–2026 (USD MILLION) 125
TABLE 124 ASIA PACIFIC: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE, 2017–2020 (USD MILLION) 125
TABLE 125 ASIA PACIFIC: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE, 2021–2026 (USD MILLION) 126
9.5 REST OF THE WORLD 126
9.5.1 GOVERNMENT INITIATIVES TO PROMOTE HEALTHCARE SERVICES TO SUPPORT MARKET GROWTH 126
TABLE 126 ROW: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 127
TABLE 127 ROW: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 127
TABLE 128 ROW: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 128
TABLE 129 ROW: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 128
TABLE 130 ROW: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 128
TABLE 131 ROW: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 129
TABLE 132 ROW: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2017–2020 (USD MILLION) 129
TABLE 133 ROW: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2021–2026 (USD MILLION) 129
TABLE 134 ROW: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2017–2020 (USD MILLION) 130
TABLE 135 ROW: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2021–2026 (USD MILLION) 130
10 COMPETITIVE LANDSCAPE 131
10.1 OVERVIEW 131
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 131
TABLE 136 OVERVIEW OF STRATEGIES ADOPTED BY KEY VASCULAR CLOSURE DEVICES MARKET PLAYERS 131
10.3 REVENUE SHARE ANALYSIS 132
FIGURE 22 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN THE VASCULAR CLOSURE DEVICES MARKET 132
10.4 MARKET SHARE ANALYSIS 133
FIGURE 23 VASCULAR CLOSURE DEVICES MARKET SHARE ANALYSIS, 2020 133
TABLE 137 VASCULAR CLOSURE DEVICES MARKET: DEGREE OF COMPETITION (2020) 134
10.5 COMPANY EVALUATION QUADRANT 135
10.5.1 STARS 135
10.5.2 EMERGING LEADERS 135
10.5.3 PERVASIVE PLAYERS 135
10.5.4 PARTICIPANTS 135
FIGURE 24 VASCULAR CLOSURE DEVICES MARKET: COMPANY EVALUATION
QUADRANT (2020) 136
10.6 COMPANY EVALUATION QUADRANT: SMES/START-UPS 137
10.6.1 PROGRESSIVE COMPANIES 137
10.6.2 STARTING BLOCKS 137
10.6.3 RESPONSIVE COMPANIES 137
10.6.4 DYNAMIC COMPANIES 137
FIGURE 25 VASCULAR CLOSURE DEVICES MARKET: COMPANY EVALUATION QUADRANT FOR SMES & START-UPS (2020) 138
10.7 COMPETITIVE SCENARIO 139
10.7.1 PRODUCT LAUNCHES & APPROVALS 139
TABLE 138 PRODUCT LAUNCHES & APPROVALS 139
10.7.2 DEALS 140
TABLE 139 DEALS 140
10.7.3 OTHER DEVELOPMENTS 141
TABLE 140 OTHER DEVELOPMENTS 141
11 COMPANY PROFILES 142
11.1 KEY PLAYERS 142
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 TERUMO CORPORATION 142
TABLE 141 TERUMO CORPORATION: BUSINESS OVERVIEW 142
FIGURE 26 TERUMO CORPORATION: COMPANY SNAPSHOT (2020) 143
TABLE 142 EXCHANGE RATES (USED FOR THE CONVERSION OF YEN TO USD) 143
11.1.2 ABBOTT LABORATORIES 145
TABLE 143 ABBOTT LABORATORIES: BUSINESS OVERVIEW 145
FIGURE 27 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020) 146
11.1.3 CARDINAL HEALTH 148
TABLE 144 CARDINAL HEALTH: BUSINESS OVERVIEW 148
FIGURE 28 CARDINAL HEALTH: COMPANY SNAPSHOT (2021) 149
11.1.4 CARDIVA MEDICAL, INC. 151
TABLE 145 CARDIVA MEDICAL, INC.: BUSINESS OVERVIEW 151
11.1.5 MEDTRONIC PLC 153
TABLE 146 MEDTRONIC PLC: BUSINESS OVERVIEW 153
FIGURE 29 MEDTRONIC PLC: COMPANY SNAPSHOT (2021) 154
11.1.6 MORRIS INNOVATIVE, INC. 156
TABLE 147 MORRIS INNOVATIVE, INC.: BUSINESS OVERVIEW 156
11.1.7 TELEFLEX INCORPORATED 157
TABLE 148 TELEFLEX INCORPORATED: BUSINESS OVERVIEW 157
FIGURE 30 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2020) 158
11.1.8 MERIT MEDICAL SYSTEMS, INC. 160
TABLE 149 MERIT MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW 160
FIGURE 31 MERIT MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2020) 161
11.1.9 VASORUM LTD. 163
TABLE 150 VASORUM LTD.: BUSINESS OVERVIEW 163
11.1.10 TZ MEDICAL, INC. 165
TABLE 151 TZ MEDICAL INC.: BUSINESS OVERVIEW 165
11.2 OTHER PLAYERS 166
11.2.1 VIVASURE MEDICAL LTD. 166
11.2.2 TRICOL BIOMEDICAL 167
11.2.3 SCION BIOMEDICAL 168
11.2.4 ADVANCED VASCULAR DYNAMICS 169
11.2.5 MARINE POLYMER TECHNOLOGIES, INC. 170
11.2.6 TRANSLUMINAL TECHNOLOGIES 171
11.2.7 REX MEDICAL 172
11.2.8 MERIL LIFE SCIENCES PVT. LTD. 173
11.2.9 MEDAS USA 174
11.2.10 VYGON COMPANY 175
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX 176
12.1 INSIGHTS FROM INDUSTRY EXPERTS 176
12.2 DISCUSSION GUIDE 177
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 180
12.4 AVAILABLE CUSTOMIZATIONS 182
12.5 RELATED REPORTS 182
12.6 AUTHOR DETAILS 183
1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 24
1.3 MARKET SCOPE 25
FIGURE 1 VASCULAR CLOSURE DEVICES MARKET SEGMENTATION 25
1.3.1 YEARS CONSIDERED FOR THE STUDY 25
1.4 CURRENCY 26
1.5 STAKEHOLDERS 26
1.6 SUMMARY OF CHANGES 26
2 RESEARCH METHODOLOGY 27
2.1 RESEARCH DATA 27
FIGURE 2 RESEARCH DESIGN 27
2.2 SECONDARY DATA 28
2.2.1 SECONDARY SOURCES 29
2.3 PRIMARY DATA 30
FIGURE 3 PRIMARY SOURCES 30
2.3.1 KEY DATA FROM PRIMARY SOURCES 31
2.3.2 KEY INDUSTRY INSIGHTS 32
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 33
2.4 MARKET SIZE ESTIMATION 33
FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 34
2.4.1 GROWTH FORECAST 35
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 35
FIGURE 7 TOP-DOWN APPROACH 36
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 37
FIGURE 8 DATA TRIANGULATION METHODOLOGY 37
2.6 MARKET SHARE ANALYSIS 38
2.7 ASSUMPTIONS FOR THE STUDY 38
2.7.1 COVID-19-SPECIFIC ASSUMPTIONS 39
2.8 LIMITATIONS 39
2.9 RISK ASSESSMENT 40
2.10 COVID-19 ECONOMIC ASSESSMENT 40
2.11 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 41
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY 41
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 42
3 EXECUTIVE SUMMARY 43
FIGURE 11 VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 43
FIGURE 12 VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2021 VS. 2026 (USD MILLION) 44
FIGURE 13 VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2021 VS. 2026 (USD MILLION) 44
FIGURE 14 VASCULAR CLOSURE DEVICES MARKET, BY REGION,
2021 VS. 2026 (USD MILLION) 45
4 PREMIUM INSIGHTS 46
4.1 VASCULAR CLOSURE DEVICES MARKET OVERVIEW 46
FIGURE 15 LARGE NUMBER OF APPROVALS FOR VASCULAR CLOSURE DEVICES TO DRIVE MARKET GROWTH 46
4.2 VASCULAR CLOSURE DEVICES MARKET, BY TYPE (2021–2026) 47
FIGURE 16 PASSIVE APPROXIMATORS SEGMENT TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 47
4.3 NORTH AMERICA: VASCULAR CLOSURE DEVICES MARKET,
BY TYPE AND COUNTRY (2020) 48
FIGURE 17 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN VASCULAR CLOSURE DEVICES MARKET IN 2020 48
4.4 VASCULAR CLOSURE DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 49
FIGURE 18 US TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 49
5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
FIGURE 19 VASCULAR CLOSURE DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50
5.2 MARKET DYNAMICS 51
5.2.1 DRIVERS 51
5.2.1.1 Growing approvals of vascular closure devices 51
TABLE 1 APPROVALS OF VASCULAR CLOSURE DEVICES 51
5.2.1.2 High prevalence of cardiovascular diseases 51
5.2.1.3 Increasing prevalence of obesity 52
5.2.1.4 Increasing focus of market players on large-bore vascular closure devices 52
5.2.1.5 Growing geriatric population 52
5.2.1.6 Favorable reimbursement scenario for interventional radiology procedures 53
TABLE 2 REIMBURSEMENTS FOR INTERVENTIONAL RADIOLOGY PROCEDURES IN THE US 53
5.2.1.7 Rising focus on effective blood loss management in patients during surgeries 54
5.2.1.8 Increasing investments, funds, and grants for research on vascular devices 54
5.2.2 RESTRAINTS 54
5.2.2.1 Increasing preference for interventional procedures using radial artery access 54
5.2.2.2 High cost of vascular closure devices 55
5.2.2.3 Product recalls and failures 55
TABLE 3 RECENT RECALLS OF VASCULAR CLOSURE DEVICES 55
5.2.3 OPPORTUNITIES 56
5.2.3.1 Emerging markets providing growth opportunities for market players 56
5.2.3.2 Growth in the number of hospitals & surgical centers 56
5.2.4 CHALLENGES 56
5.2.4.1 Need for highly skilled professionals 56
5.2.4.2 Risks associated with vascular closure devices 57
5.2.4.3 Stringent regulatory frameworks 57
5.3 COVID-19 IMPACT ON THE VASCULAR CLOSURE DEVICES MARKET 58
6 VASCULAR CLOSURE DEVICES MARKET, BY TYPE 60
6.1 INTRODUCTION 61
TABLE 4 VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 61
TABLE 5 VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 61
6.2 PASSIVE APPROXIMATORS 62
TABLE 6 PASSIVE APPROXIMATORS MARKET, BY TYPE, 2017–2020 (USD MILLION) 62
TABLE 7 PASSIVE APPROXIMATORS MARKET, BY TYPE, 2021–2026 (USD MILLION) 62
TABLE 8 PASSIVE APPROXIMATORS MARKET, BY REGION, 2017–2020 (USD MILLION) 63
TABLE 9 PASSIVE APPROXIMATORS MARKET, BY REGION, 2021–2026 (USD MILLION) 63
6.2.1 COLLAGEN PLUGS 63
6.2.1.1 Growing number of approvals for collagen-based vascular closure devices to drive market growth during the forecast period 63
TABLE 10 COLLAGEN PLUGS MARKET, BY REGION, 2017–2020 (USD MILLION) 64
TABLE 11 COLLAGEN PLUGS MARKET, BY REGION, 2021–2026 (USD MILLION) 64
6.2.2 SEALANT OR GEL-BASED DEVICES 65
6.2.2.1 Sealant or gel-based devices to register the highest growth rate during the forecast period 65
TABLE 12 SEALANT OR GEL-BASED DEVICES MARKET, BY REGION,
2017–2020 (USD MILLION) 65
TABLE 13 SEALANT OR GEL-BASED DEVICES MARKET, BY REGION,
2021–2026 (USD MILLION) 66
6.2.3 COMPRESSION ASSIST DEVICES 66
6.2.3.1 Compression assist devices do not leave behind any foreign body in the tissue artery—a major advantage of these devices 66
TABLE 14 COMPRESSION ASSIST DEVICES MARKET, BY REGION,
2017–2020 (USD MILLION) 66
TABLE 15 COMPRESSION ASSIST DEVICES MARKET, BY REGION,
2021–2026 (USD MILLION) 67
6.3 ACTIVE APPROXIMATORS 67
TABLE 16 ACTIVE APPROXIMATORS MARKET, BY TYPE, 2017–2020 (USD MILLION) 67
TABLE 17 ACTIVE APPROXIMATORS MARKET, BY TYPE, 2021–2026 (USD MILLION) 68
TABLE 18 ACTIVE APPROXIMATORS MARKET, BY REGION, 2017–2020 (USD MILLION) 68
TABLE 19 ACTIVE APPROXIMATORS MARKET, BY REGION, 2021–2026 (USD MILLION) 68
6.3.1 SUTURE-BASED DEVICES 69
6.3.1.1 Increasing applications of suture-based devices to
favor market growth 69
TABLE 20 SUTURE-BASED ACTIVE APPROXIMATORS MARKET, BY REGION,
2017–2020 (USD MILLION) 69
TABLE 21 SUTURE-BASED ACTIVE APPROXIMATORS MARKET, BY REGION,
2021–2026 (USD MILLION) 70
6.3.2 CLIP-BASED DEVICES 70
6.3.2.1 Growing innovation in the field of clip-based devices to aid market growth 70
TABLE 22 CLIP-BASED ACTIVE APPROXIMATORS MARKET, BY REGION,
2017–2020 (USD MILLION) 71
TABLE 23 CLIP-BASED ACTIVE APPROXIMATORS MARKET, BY REGION,
2021–2026 (USD MILLION) 71
6.4 EXTERNAL HEMOSTATIC DEVICES 71
6.4.1 RISING ADOPTION OF MINIMALLY INVASIVE THERAPEUTIC PROCEDURES TO DRIVE MARKET GROWTH 71
TABLE 24 EXTERNAL HEMOSTATIC DEVICES MARKET, BY REGION,
2017–2020 (USD MILLION) 72
TABLE 25 EXTERNAL HEMOSTATIC DEVICES MARKET, BY REGION,
2021–2026 (USD MILLION) 72
7 VASCULAR CLOSURE DEVICES MARKET, BY ACCESS 73
7.1 INTRODUCTION 74
TABLE 26 VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2017–2020 (USD MILLION) 74
TABLE 27 VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2021–2026 (USD MILLION) 74
7.2 FEMORAL ACCESS 75
7.2.1 ADVANTAGES ASSOCIATED WITH FEMORAL ACCESS, SUCH AS GREATER COMFORT LEVEL FOR PATIENTS AND REDUCED COST OF HOSPITALIZATION, TO DRIVE MARKET GROWTH 75
TABLE 28 FEMORAL ACCESS: RESEARCH STUDIES 75
TABLE 29 FEMORAL ACCESS VASCULAR CLOSURE DEVICES MARKET, BY REGION, 2017–2020 (USD MILLION) 76
TABLE 30 FEMORAL ACCESS VASCULAR CLOSURE DEVICES MARKET, BY REGION, 2021–2026 (USD MILLION) 76
7.3 RADIAL ACCESS 77
7.3.1 TRANSRADIAL APPROACH REDUCES VASCULAR COMPLICATIONS COMPARED TO THE FEMORAL ARTERY ACCESS APPROACH—A KEY FACTOR DRIVING MARKET GROWTH 77
TABLE 31 RADIAL ACCESS VASCULAR CLOSURE DEVICES MARKET, BY REGION,
2017–2020 (USD MILLION) 77
TABLE 32 RADIAL ACCESS VASCULAR CLOSURE DEVICES MARKET, BY REGION,
2021–2026 (USD MILLION) 78
8 VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE 79
8.1 INTRODUCTION 80
TABLE 33 VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2017–2020 (USD MILLION) 80
TABLE 34 VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2021–2026 (USD MILLION) 80
8.2 INTERVENTIONAL CARDIOLOGY 81
8.2.1 ASSOCIATED BENEFITS OF INTERVENTIONAL CARDIOLOGY PROCEDURES, SUCH AS REDUCED SCARRING AND LESS PAIN, TO DRIVE MARKET GROWTH 81
TABLE 35 VASCULAR CLOSURE DEVICES MARKET FOR INTERVENTIONAL CARDIOLOGY PROCEDURES, BY REGION, 2017–2020 (USD MILLION) 82
TABLE 36 VASCULAR CLOSURE DEVICES MARKET FOR INTERVENTIONAL CARDIOLOGY PROCEDURES, BY REGION, 2021–2026 (USD MILLION) 82
8.3 INTERVENTIONAL RADIOLOGY/VASCULAR SURGERY 83
8.3.1 GROWTH IN THE PREVALENCE OF PAD IS INCREASING THE DEMAND FOR ENDOVASCULAR INTERVENTIONAL PROCEDURES 83
TABLE 37 VASCULAR CLOSURE DEVICES MARKET FOR INTERVENTIONAL RADIOLOGY/VASCULAR SURGERY PROCEDURES, BY REGION,
2017–2020 (USD MILLION) 83
TABLE 38 VASCULAR CLOSURE DEVICES MARKET FOR INTERVENTIONAL RADIOLOGY/VASCULAR SURGERY PROCEDURES, BY REGION,
2021–2026 (USD MILLION) 84
9 VASCULAR CLOSURE DEVICES MARKET, BY REGION 85
9.1 INTRODUCTION 86
TABLE 39 VASCULAR CLOSURE DEVICES MARKET, BY REGION,
2017–2020 (USD MILLION) 86
TABLE 40 VASCULAR CLOSURE DEVICES MARKET, BY REGION,
2021–2026 (USD MILLION) 86
9.2 NORTH AMERICA 87
FIGURE 20 NORTH AMERICA: VASCULAR CLOSURE DEVICES MARKET SNAPSHOT 88
TABLE 41 NORTH AMERICA: VASCULAR CLOSURE DEVICES MARKET, BY COUNTRY, 2017–2020 (USD MILLION) 88
TABLE 42 NORTH AMERICA: VASCULAR CLOSURE DEVICES MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 89
TABLE 43 NORTH AMERICA: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 89
TABLE 44 NORTH AMERICA: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 89
TABLE 45 NORTH AMERICA: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 90
TABLE 46 NORTH AMERICA: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 90
TABLE 47 NORTH AMERICA: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 90
TABLE 48 NORTH AMERICA: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 91
TABLE 49 NORTH AMERICA: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS, 2017–2020 (USD MILLION) 91
TABLE 50 NORTH AMERICA: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS, 2021–2026 (USD MILLION) 91
TABLE 51 NORTH AMERICA: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE, 2017–2020 (USD MILLION) 92
TABLE 52 NORTH AMERICA: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE, 2021–2026 (USD MILLION) 92
9.2.1 US 92
9.2.1.1 The US dominates the North American vascular closure
devices market 92
TABLE 53 REIMBURSEMENTS FOR INTERVENTIONAL CARDIOLOGY PROCEDURES, 2020 93
TABLE 54 US: KEY MACROINDICATORS 94
TABLE 55 US: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 94
TABLE 56 US: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 95
TABLE 57 US: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 95
TABLE 58 US: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 95
TABLE 59 US: ACTIVE APPROXIMATORS MARKET, BY TYPE, 2017–2020 (USD MILLION) 96
TABLE 60 US: ACTIVE APPROXIMATORS MARKET, BY TYPE, 2021–2026 (USD MILLION) 96
TABLE 61 US: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2017–2020 (USD MILLION) 96
TABLE 62 US: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2021–2026 (USD MILLION) 97
TABLE 63 US: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2017–2020 (USD MILLION) 97
TABLE 64 US: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2021–2026 (USD MILLION) 97
9.2.2 CANADA 98
9.2.2.1 Rising prevalence of target diseases to drive market growth 98
TABLE 65 CANADA: KEY MACROINDICATORS 98
TABLE 66 CANADA: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 99
TABLE 67 CANADA: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 99
TABLE 68 CANADA: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 99
TABLE 69 CANADA: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 100
TABLE 70 CANADA: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 100
TABLE 71 CANADA: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 100
TABLE 72 CANADA: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2017–2020 (USD MILLION) 101
TABLE 73 CANADA: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2021–2026 (USD MILLION) 101
TABLE 74 CANADA: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2017–2020 (USD MILLION) 101
TABLE 75 CANADA: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2021–2026 (USD MILLION) 102
9.3 EUROPE 102
TABLE 76 NUMBER OF SURGICAL PROCEDURES PER 100,000 POPULATION,
BY COUNTRY, 2018 102
TABLE 77 EUROPE: VASCULAR CLOSURE DEVICES MARKET, BY COUNTRY,
2017–2020 (USD MILLION) 103
TABLE 78 EUROPE: VASCULAR CLOSURE DEVICES MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 103
TABLE 79 EUROPE: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 103
TABLE 80 EUROPE: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 104
TABLE 81 EUROPE: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 104
TABLE 82 EUROPE: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 104
TABLE 83 EUROPE: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 105
TABLE 84 EUROPE: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 105
TABLE 85 EUROPE: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2017–2020 (USD MILLION) 105
TABLE 86 EUROPE: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2021–2026 (USD MILLION) 106
TABLE 87 EUROPE: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2017–2020 (USD MILLION) 106
TABLE 88 EUROPE: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2021–2026 (USD MILLION) 106
9.3.1 E-3 107
9.3.1.1 Increase in number of radial procedures to boost the market demand 107
TABLE 89 GERMANY: KEY MACROINDICATORS 107
TABLE 90 UK: KEY MACROINDICATORS 108
TABLE 91 FRANCE: KEY MACROINDICATORS 109
TABLE 92 E-3: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 110
TABLE 93 E-3: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 110
TABLE 94 E-3: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 110
TABLE 95 E-3: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 111
TABLE 96 E-3: ACTIVE APPROXIMATORS MARKET, BY TYPE, 2017–2020 (USD MILLION) 111
TABLE 97 E-3: ACTIVE APPROXIMATORS MARKET, BY TYPE, 2021–2026 (USD MILLION) 111
TABLE 98 E-3: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2017–2020 (USD MILLION) 112
TABLE 99 E-3: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2021–2026 (USD MILLION) 112
TABLE 100 E-3: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2017–2020 (USD MILLION) 112
TABLE 101 E-3: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2021–2026 (USD MILLION) 113
9.3.2 REST OF EUROPE 113
TABLE 102 ROE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2018 (% OF GDP) 114
TABLE 103 ROE: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 114
TABLE 104 ROE: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 115
TABLE 105 ROE: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 115
TABLE 106 ROE: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 115
TABLE 107 ROE: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 116
TABLE 108 ROE: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 116
TABLE 109 ROE: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2017–2020 (USD MILLION) 116
TABLE 110 ROE: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2021–2026 (USD MILLION) 117
TABLE 111 ROE: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2017–2020 (USD MILLION) 117
TABLE 112 ROE: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2021–2026 (USD MILLION) 117
9.4 ASIA PACIFIC 118
9.4.1 INCREASING HEALTH EXPENDITURE TO DRIVE MARKET GROWTH IN APAC 118
FIGURE 21 ASIA PACIFIC: VASCULAR CLOSURE DEVICES MARKET SNAPSHOT 119
TABLE 113 CHINA: KEY MACROINDICATORS 120
TABLE 114 JAPAN: KEY MACROINDICATORS 121
TABLE 115 INDIA: KEY INDICATORS 122
TABLE 116 ASIA PACIFIC: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 123
TABLE 117 ASIA PACIFIC: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 123
TABLE 118 ASIA PACIFIC: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 123
TABLE 119 ASIA PACIFIC: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 124
TABLE 120 ASIA PACIFIC: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 124
TABLE 121 ASIA PACIFIC: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 124
TABLE 122 ASIA PACIFIC: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2017–2020 (USD MILLION) 125
TABLE 123 ASIA PACIFIC: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2021–2026 (USD MILLION) 125
TABLE 124 ASIA PACIFIC: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE, 2017–2020 (USD MILLION) 125
TABLE 125 ASIA PACIFIC: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE, 2021–2026 (USD MILLION) 126
9.5 REST OF THE WORLD 126
9.5.1 GOVERNMENT INITIATIVES TO PROMOTE HEALTHCARE SERVICES TO SUPPORT MARKET GROWTH 126
TABLE 126 ROW: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2017–2020 (USD MILLION) 127
TABLE 127 ROW: VASCULAR CLOSURE DEVICES MARKET, BY TYPE,
2021–2026 (USD MILLION) 127
TABLE 128 ROW: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 128
TABLE 129 ROW: PASSIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 128
TABLE 130 ROW: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2017–2020 (USD MILLION) 128
TABLE 131 ROW: ACTIVE APPROXIMATORS MARKET, BY TYPE,
2021–2026 (USD MILLION) 129
TABLE 132 ROW: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2017–2020 (USD MILLION) 129
TABLE 133 ROW: VASCULAR CLOSURE DEVICES MARKET, BY ACCESS,
2021–2026 (USD MILLION) 129
TABLE 134 ROW: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2017–2020 (USD MILLION) 130
TABLE 135 ROW: VASCULAR CLOSURE DEVICES MARKET, BY PROCEDURE,
2021–2026 (USD MILLION) 130
10 COMPETITIVE LANDSCAPE 131
10.1 OVERVIEW 131
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 131
TABLE 136 OVERVIEW OF STRATEGIES ADOPTED BY KEY VASCULAR CLOSURE DEVICES MARKET PLAYERS 131
10.3 REVENUE SHARE ANALYSIS 132
FIGURE 22 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN THE VASCULAR CLOSURE DEVICES MARKET 132
10.4 MARKET SHARE ANALYSIS 133
FIGURE 23 VASCULAR CLOSURE DEVICES MARKET SHARE ANALYSIS, 2020 133
TABLE 137 VASCULAR CLOSURE DEVICES MARKET: DEGREE OF COMPETITION (2020) 134
10.5 COMPANY EVALUATION QUADRANT 135
10.5.1 STARS 135
10.5.2 EMERGING LEADERS 135
10.5.3 PERVASIVE PLAYERS 135
10.5.4 PARTICIPANTS 135
FIGURE 24 VASCULAR CLOSURE DEVICES MARKET: COMPANY EVALUATION
QUADRANT (2020) 136
10.6 COMPANY EVALUATION QUADRANT: SMES/START-UPS 137
10.6.1 PROGRESSIVE COMPANIES 137
10.6.2 STARTING BLOCKS 137
10.6.3 RESPONSIVE COMPANIES 137
10.6.4 DYNAMIC COMPANIES 137
FIGURE 25 VASCULAR CLOSURE DEVICES MARKET: COMPANY EVALUATION QUADRANT FOR SMES & START-UPS (2020) 138
10.7 COMPETITIVE SCENARIO 139
10.7.1 PRODUCT LAUNCHES & APPROVALS 139
TABLE 138 PRODUCT LAUNCHES & APPROVALS 139
10.7.2 DEALS 140
TABLE 139 DEALS 140
10.7.3 OTHER DEVELOPMENTS 141
TABLE 140 OTHER DEVELOPMENTS 141
11 COMPANY PROFILES 142
11.1 KEY PLAYERS 142
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 TERUMO CORPORATION 142
TABLE 141 TERUMO CORPORATION: BUSINESS OVERVIEW 142
FIGURE 26 TERUMO CORPORATION: COMPANY SNAPSHOT (2020) 143
TABLE 142 EXCHANGE RATES (USED FOR THE CONVERSION OF YEN TO USD) 143
11.1.2 ABBOTT LABORATORIES 145
TABLE 143 ABBOTT LABORATORIES: BUSINESS OVERVIEW 145
FIGURE 27 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020) 146
11.1.3 CARDINAL HEALTH 148
TABLE 144 CARDINAL HEALTH: BUSINESS OVERVIEW 148
FIGURE 28 CARDINAL HEALTH: COMPANY SNAPSHOT (2021) 149
11.1.4 CARDIVA MEDICAL, INC. 151
TABLE 145 CARDIVA MEDICAL, INC.: BUSINESS OVERVIEW 151
11.1.5 MEDTRONIC PLC 153
TABLE 146 MEDTRONIC PLC: BUSINESS OVERVIEW 153
FIGURE 29 MEDTRONIC PLC: COMPANY SNAPSHOT (2021) 154
11.1.6 MORRIS INNOVATIVE, INC. 156
TABLE 147 MORRIS INNOVATIVE, INC.: BUSINESS OVERVIEW 156
11.1.7 TELEFLEX INCORPORATED 157
TABLE 148 TELEFLEX INCORPORATED: BUSINESS OVERVIEW 157
FIGURE 30 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2020) 158
11.1.8 MERIT MEDICAL SYSTEMS, INC. 160
TABLE 149 MERIT MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW 160
FIGURE 31 MERIT MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2020) 161
11.1.9 VASORUM LTD. 163
TABLE 150 VASORUM LTD.: BUSINESS OVERVIEW 163
11.1.10 TZ MEDICAL, INC. 165
TABLE 151 TZ MEDICAL INC.: BUSINESS OVERVIEW 165
11.2 OTHER PLAYERS 166
11.2.1 VIVASURE MEDICAL LTD. 166
11.2.2 TRICOL BIOMEDICAL 167
11.2.3 SCION BIOMEDICAL 168
11.2.4 ADVANCED VASCULAR DYNAMICS 169
11.2.5 MARINE POLYMER TECHNOLOGIES, INC. 170
11.2.6 TRANSLUMINAL TECHNOLOGIES 171
11.2.7 REX MEDICAL 172
11.2.8 MERIL LIFE SCIENCES PVT. LTD. 173
11.2.9 MEDAS USA 174
11.2.10 VYGON COMPANY 175
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX 176
12.1 INSIGHTS FROM INDUSTRY EXPERTS 176
12.2 DISCUSSION GUIDE 177
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 180
12.4 AVAILABLE CUSTOMIZATIONS 182
12.5 RELATED REPORTS 182
12.6 AUTHOR DETAILS 183
MarketsandMarkets
Publisher: MarketsandMarkets
# of Pages: 224
Rating:
1 User License $4,950
Publication Date: April, 2022
Price: $4,950 / User License
Buy Now
RPT50593
LIC503
1 User $4,950
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.2.1 CATEGORY-WISE INCLUSIONS AND EXCLUSIONS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 33
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
FIGURE 1 LATERAL FLOW ASSAY COMPONENTS MARKET SEGMENTATION 34
1.3.2 YEARS CONSIDERED FOR THE STUDY 35
1.4 CURRENCY 35
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 35
1.5 STAKEHOLDERS 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH APPROACH 36
FIGURE 2 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 37
2.1.2 PRIMARY DATA 38
2.1.2.1 Primary sources 38
2.1.2.2 Key data from primary sources 39
2.1.2.3 Breakdown of primaries 39
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE):
BY COMPANY TYPE, DESIGNATION, AND REGION 39
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 40
2.2 MARKET SIZE ESTIMATION 40
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021) 41
FIGURE 6 SUPPLY-SIDE ANALYSIS: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 42
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 44
FIGURE 7 DATA TRIANGULATION METHODOLOGY 45
2.4 KEY INDUSTRY INSIGHTS 46
2.5 LIMITATIONS 46
2.5.1 METHODOLOGY-RELATED LIMITATIONS 46
2.6 RISK ASSESSMENT 47
2.7 ASSUMPTIONS FOR THE STUDY 47
3 EXECUTIVE SUMMARY 48
FIGURE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 48
FIGURE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2022 VS. 2027 (USD MILLION) 49
FIGURE 10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 50
FIGURE 11 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 51
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 52
4 PREMIUM INSIGHTS 53
4.1 LATERAL FLOW ASSAY COMPONENTS MARKET OVERVIEW 53
FIGURE 13 RISING NUMBER OF LOCAL MANUFACTURERS FOR COMPONENTS IS DRIVING THE GROWTH OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 53
4.2 REGIONAL MIX: LATERAL FLOW ASSAY COMPONENTS MARKET 54
FIGURE 14 APAC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 54
4.3 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE AND COUNTRY 55
FIGURE 15 MEMBRANES ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021 55
4.4 LATERAL FLOW ASSAY COMPONENTS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 56
4.5 LATERAL FLOW ASSAY COMPONENTS MARKET: DEVELOPED VS. DEVELOPING COUNTRIES 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS: IMPACT ANALYSIS 57
5.2.1 DRIVERS 58
5.2.1.1 Growing demand for lateral flow assay kits due
to the COVID-19 pandemic 58
5.2.1.2 Growing usage of home-based lateral flow assay devices 58
5.2.1.3 Growing demand for point-of-care testing 58
5.2.1.4 Increasing public-private investments to develop lateral flow assays 59
5.2.2 RESTRAINTS 59
5.2.2.1 Availability of alternative diagnostic technologies 59
5.2.3 OPPORTUNITIES 59
5.2.3.1 Evolving applications of lateral flow assays 59
5.2.4 CHALLENGES 60
5.2.4.1 Requirement of specialized storage and shipping facilities for membranes 60
5.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES (YC-YCC) IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
FIGURE 16 YC–YCC SHIFT IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 61
5.5 AVERAGE SELLING PRICE TREND 61
TABLE 2 AVERAGE SELLING PRICE OF LATERAL FLOW ASSAY COMPONENTS,
BY REGION, 2021 (USD) 61
5.6 ECOSYSTEM MARKET MAP 62
FIGURE 17 ECOSYSTEM: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 62
5.7 PATENT ANALYSIS 63
5.7.1 PATENT PUBLICATION TRENDS FOR LATERAL FLOW ASSAYS 63
FIGURE 18 GLOBAL PATENT PUBLICATION TRENDS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2016–2021 64
5.7.2 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 64
FIGURE 19 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LATERAL FLOW ASSAYS COMPONENTS, 2016–2021 64
5.8 VALUE CHAIN ANALYSIS 65
5.9 REGULATORY LANDSCAPE 66
TABLE 3 REGULATORY STANDARDS/APPROVALS REQUIRED FOR LATERAL FLOW IMMUNOASSAY PRODUCTS, BY COUNTRY/REGION 66
5.9.1 NORTH AMERICA 66
5.9.2 EUROPE 67
5.9.3 ASIA PACIFIC 67
5.9.3.1 India 67
5.9.3.2 China 67
5.9.3.3 Japan 68
5.10 TECHNOLOGY ANALYSIS 69
5.10.1 KEY TECHNOLOGY: LATERAL FLOW ASSAYS 69
5.11 KEY CONFERENCES & EVENTS DURING 2021–2023 69
TABLE 4 LATERAL FLOW ASSAY COMPONENTS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 69
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 70
5.12.1 KEY STAKEHOLDERS IN THE BUYING PROCESS 70
FIGURE 20 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
TABLE 5 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
5.12.2 BUYING CRITERIA 71
FIGURE 21 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
TABLE 6 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
5.13 PORTER’S FIVE FORCES ANALYSIS 72
TABLE 7 LATERAL FLOW ASSAY COMPONENTS MARKET:
PORTER’S FIVE FORCES ANALYSIS 72
5.13.1 THREAT FROM NEW ENTRANTS 72
5.13.2 THREAT FROM SUBSTITUTES 72
5.13.3 BARGAINING POWER OF BUYERS 73
5.13.4 BARGAINING POWER OF SUPPLIERS 73
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 73
6 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE 74
6.1 INTRODUCTION 75
TABLE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 75
6.2 MEMBRANES 75
TABLE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE,
2020–2027 (USD MILLION) 76
TABLE 10 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 76
6.2.1 NITROCELLULOSE MEMBRANES 77
6.2.1.1 Advantages of nitrocellulose membranes such as high protein-binding affinity and compatibility with a wide range of detection methods to drive market growth 77
TABLE 11 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 12 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (1 X 1 M SHEETS), BY REGION, 2020–2027 (IN THOUSANDS) 78
TABLE 13 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (20 MM X 1 M ROLLS), BY REGION, 2020–2027 (IN MILLIONS) 78
6.2.2 OTHER MEMBRANES 78
TABLE 14 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 79
6.3 PADS 80
TABLE 15 EXAMPLES OF DIFFERENT MATERIALS USED IN MANUFACTURING LATERAL FLOW ASSAY PADS 80
TABLE 16 LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 80
TABLE 17 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PADS, BY COUNTRY, 2020–2027 (USD MILLION) 81
6.3.1 SAMPLE PADS 81
6.3.1.1 Ability to promote even and controlled distribution of samples to drive market growth 81
TABLE 18 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SAMPLE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 82
6.3.2 CONJUGATE PADS 82
6.3.2.1 Conjugate pads play an important role in controlling the performance of lateral flow immunoassays 82
TABLE 19 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CONJUGATE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 83
6.3.3 ABSORBENT PADS 84
6.3.3.1 Absorbent pads prevent backflow—a key factor driving market growth 84
TABLE 20 LATERAL FLOW ASSAY COMPONENTS MARKET FOR ABSORBENT PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 84
6.4 OTHER COMPONENTS 84
TABLE 21 OTHER LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 85
7 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION 86
7.1 INTRODUCTION 87
TABLE 22 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 87
7.2 CLINICAL TESTING 87
TABLE 23 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 24 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 88
7.2.1 INFECTIOUS DISEASE TESTING 89
7.2.1.1 Rising demand for infectious disease testing in emerging markets to drive market growth 89
TABLE 25 LATERAL FLOW ASSAY COMPONENTS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 89
7.2.2 PREGNANCY & FERTILITY TESTING 90
7.2.2.1 Growing infertility levels due to changing lifestyles—a key factor driving market growth 90
TABLE 26 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PREGNANCY & FERTILITY TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 90
7.2.3 CARDIAC MARKER TESTING 91
7.2.3.1 Rising prevalence of cardiovascular diseases and growing government support to drive growth in this market segment 91
TABLE 27 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CARDIAC MARKER TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 92
7.2.4 CHOLESTEROL TESTING/LIPID PROFILING 92
7.2.4.1 Growing prevalence of obesity and CVD—
a key factor driving market growth 92
TABLE 28 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CHOLESTEROL TESTING/LIPID PROFILING, BY COUNTRY, 2020–2027 (USD MILLION) 93
7.2.5 DRUGS-OF-ABUSE TESTING 93
7.2.5.1 Technological advancements and a growing focus on workplace
drug testing are driving market growth 93
TABLE 29 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUGS-OF-ABUSE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 94
7.2.6 OTHER CLINICAL TESTING APPLICATIONS 94
TABLE 30 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER CLINICAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 95
7.3 VETERINARY DIAGNOSTICS 95
7.3.1 INFECTIOUS DISEASE OUTBREAKS (PARTICULARLY IN LARGE LIVESTOCK ANIMALS) TO DRIVE MARKET GROWTH 95
TABLE 31 LATERAL FLOW ASSAY COMPONENTS MARKET FOR VETERINARY DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 96
7.4 FOOD SAFETY & ENVIRONMENTAL TESTING 96
7.4.1 HIGH SENSITIVITY AND EASE OF USE ARE KEY FACTORS DRIVING THE DEMAND FOR LATERAL FLOW ASSAYS FOR FOOD SAFETY TESTING 96
TABLE 32 LATERAL FLOW ASSAY COMPONENTS MARKET FOR FOOD SAFETY & ENVIRONMENTAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
7.5 DRUG DEVELOPMENT & QUALITY TESTING 97
7.5.1 INCREASING FOCUS ON PRODUCT SAFETY AND QUALITY ASSURANCE TO DRIVE MARKET GROWTH IN THE COMING YEARS 97
TABLE 33 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUG DEVELOPMENT & QUALITY TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 98
8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE 99
8.1 INTRODUCTION 100
TABLE 34 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 100
8.2 SANDWICH ASSAYS 100
8.2.1 SANDWICH ASSAYS PROVIDE HIGHER LEVELS OF ASSAY SENSITIVITY AND SPECIFICITY THAN OTHER ASSAY TECHNIQUES—A KEY FACTOR DRIVING GROWTH IN THIS MARKET SEGMENT 100
TABLE 35 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SANDWICH ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 101
8.3 COMPETITIVE ASSAYS 101
8.3.1 REDUCED SELECTIVITY AND SENSITIVITY OF COMPETITIVE ASSAYS IN RELATION TO SANDWICH ASSAYS COULD HAMPER MARKET GROWTH 101
TABLE 36 LATERAL FLOW ASSAY COMPONENTS MARKET FOR COMPETITIVE ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 102
8.4 MULTIPLEX DETECTION ASSAYS 102
8.4.1 INCREASING ADOPTION OF MULTI-ANALYTE ASSAYS AMONG CLINICIANS TO DRIVE MARKET GROWTH 102
TABLE 37 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MULTIPLEX DETECTION ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION) 103
9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER 104
9.1 INTRODUCTION 105
TABLE 38 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 105
9.2 MEDICAL DEVICE MANUFACTURING COMPANIES 105
9.2.1 INCREASING USE OF POC TESTS IS DRIVING THE ADOPTION OF LATERAL FLOW ASSAY COMPONENTS AMONG MEDICAL DEVICE MANUFACTURING COMPANIES 105
TABLE 39 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE MANUFACTURING COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 106
9.3 MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES 106
9.3.1 GROWING INCLINATION TOWARD FAST AND EARLY DIAGNOSIS, ESPECIALLY IN RELATION TO THE CURRENT COVID-19 SCENARIO, WILL DRIVE MARKET GROWTH 106
TABLE 40 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES, BY COUNTRY,
2020–2027 (USD MILLION) 107
10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION 108
10.1 INTRODUCTION 109
FIGURE 22 CHINA TO REGISTER THE HIGHEST GROWTH IN THE LATERAL FLOW ASSAY COMPONENTS MARKET DURING THE FORECAST PERIOD 109
TABLE 41 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION,
2020–2027 (USD MILLION) 110
10.2 NORTH AMERICA 110
TABLE 42 NORTH AMERICA: MACROECONOMIC INDICATORS 110
FIGURE 23 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 111
TABLE 43 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 44 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 45 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 112
TABLE 46 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 113
TABLE 47 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 113
TABLE 48 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 49 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 114
TABLE 50 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 115
10.2.1 US 115
10.2.1.1 Increasing R&D investments and venture capital funding from both large and small firms towards the development of lateral flow assay diagnostics to drive market growth in the US 115
TABLE 51 US: MACROECONOMIC INDICATORS 116
TABLE 52 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 116
TABLE 53 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 116
TABLE 54 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 117
TABLE 55 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 117
TABLE 56 US: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 57 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 118
TABLE 58 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 119
10.2.2 CANADA 119
10.2.2.1 Lateral flow assay components market in Canada is estimated to grow at a relatively lower rate than the US 119
TABLE 59 CANADA: MACROECONOMIC INDICATORS 119
TABLE 60 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 120
TABLE 61 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 120
TABLE 62 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 120
TABLE 63 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 64 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 65 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 122
TABLE 66 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 122
10.3 EUROPE 122
TABLE 67 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 68 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 123
TABLE 69 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 123
TABLE 70 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 124
TABLE 71 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 124
TABLE 72 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 73 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 125
TABLE 74 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 126
10.3.1 GERMANY 126
10.3.1.1 Growing demand for POC testing to drive the lateral flow assay components market in Germany 126
TABLE 75 GERMANY: MACROECONOMIC INDICATORS 126
TABLE 76 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 127
TABLE 77 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 127
TABLE 78 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 127
TABLE 79 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 80 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 81 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 129
TABLE 82 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 129
10.3.2 FRANCE 129
10.3.2.1 High prevalence of age-related chronic diseases and infectious diseases to drive market growth in France 129
TABLE 83 FRANCE: MACROECONOMIC INDICATORS 130
TABLE 84 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 130
TABLE 85 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 130
TABLE 86 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 131
TABLE 87 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
TABLE 88 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 89 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 132
TABLE 90 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 133
10.3.3 UK 133
10.3.3.1 Severe impact of the second wave of COVID-19 in the first half of 2021 resulted in higher adoption of rapid COVID tests in the UK 133
TABLE 91 UK: MACROECONOMIC INDICATORS 134
TABLE 92 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 134
TABLE 93 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 134
TABLE 94 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 135
TABLE 95 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 135
TABLE 96 UK: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 97 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 136
TABLE 98 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 137
10.3.4 ITALY 137
10.3.4.1 Growing initiatives towards decentralization of medical services in Italy are contributing to the market growth in the country 137
TABLE 99 ITALY: MACROECONOMIC INDICATORS 137
TABLE 100 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 138
TABLE 101 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 138
TABLE 102 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 138
TABLE 103 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139
TABLE 104 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 105 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 140
TABLE 106 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 140
10.3.5 SPAIN 140
10.3.5.1 Increasing focus of international organizations and domestic players on the development of POC products in the country to drive market growth 140
TABLE 107 SPAIN: MACROECONOMIC INDICATORS 141
TABLE 108 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 141
TABLE 109 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 142
TABLE 110 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 142
TABLE 111 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 112 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 113 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 143
TABLE 114 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 144
10.3.6 REST OF EUROPE 144
TABLE 115 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 144
TABLE 116 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 145
TABLE 117 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 145
TABLE 118 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 119 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 120 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 146
TABLE 121 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 147
10.4 ASIA PACIFIC 147
FIGURE 24 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 148
TABLE 122 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 149
TABLE 123 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 149
TABLE 124 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 149
TABLE 125 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 150
TABLE 126 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 150
TABLE 127 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 128 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 151
TABLE 129 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 152
10.4.1 CHINA 152
10.4.1.1 Higher exports of lateral flow assay components during the COVID-19 pandemic to drive market growth in the country 152
TABLE 130 CHINA: MACROECONOMIC INDICATORS 153
TABLE 131 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 153
TABLE 132 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 153
TABLE 133 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 154
TABLE 134 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 154
TABLE 135 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 136 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 155
TABLE 137 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 156
10.4.2 JAPAN 156
10.4.2.1 Increasing prevalence of age-related illnesses driving the growth of the lateral flow assay components market in Japan 156
TABLE 138 JAPAN: MACROECONOMIC INDICATORS 157
TABLE 139 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 157
TABLE 140 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 157
TABLE 141 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 158
TABLE 142 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 158
TABLE 143 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 144 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 159
TABLE 145 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 160
10.4.3 INDIA 160
10.4.3.1 Increasing number of local manufacturers, growing healthcare concerns, and rising income levels to propel the growth of this market 160
TABLE 146 INDIA: MACROECONOMIC INDICATORS 160
TABLE 147 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 161
TABLE 148 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 161
TABLE 149 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 161
TABLE 150 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 162
TABLE 151 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 152 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 163
TABLE 153 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 163
10.4.4 AUSTRALIA 164
10.4.4.1 Increasing prevalence of infectious diseases, especially influenza, to drive the growth of the lateral flow assay components market in Australia 164
TABLE 154 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 164
TABLE 155 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 164
TABLE 156 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 165
TABLE 157 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 165
TABLE 158 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 159 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 166
TABLE 160 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 167
10.4.5 REST OF ASIA PACIFIC 167
TABLE 161 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 167
TABLE 162 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 168
TABLE 163 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 168
TABLE 164 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 168
TABLE 165 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 169
TABLE 166 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 169
TABLE 167 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 170
10.5 LATIN AMERICA 170
10.5.1 HIGH DEMAND FOR HIV POC DEVICES IN THE REGION TO SUPPORT THE GROWTH OF THE MARKET 170
TABLE 168 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 169 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 171
TABLE 170 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD
TYPE, 2020–2027 (USD MILLION) 171
TABLE 171 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 172
TABLE 172 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 173 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 173
TABLE 174 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 173
10.6 MIDDLE EAST & AFRICA 173
10.6.1 SIGNIFICANT SUPPORT FROM GOVERNMENTS AND GLOBAL FIRMS TOWARDS EXPANDING HEALTHCARE SERVICES DRIVES THE ADOPTION OF LATERAL FLOW ASSAYS 173
TABLE 175 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 174
TABLE 176 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 177 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 175
TABLE 178 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 175
TABLE 179 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 175
TABLE 180 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 181 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 176
TABLE 182 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 177
11 COMPETITIVE LANDSCAPE 178
11.1 OVERVIEW 178
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 178
FIGURE 25 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
11.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
FIGURE 26 REVENUE SHARE ANALYSIS FOR THE KEY PLAYERS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 180
11.4 MARKET SHARE ANALYSIS 180
FIGURE 27 LATERAL FLOW ASSAY COMPONENTS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 181
TABLE 183 LATERAL FLOW ASSAY COMPONENTS MARKET: DEGREE OF COMPETITION 182
11.5 R&D ASSESSMENT OF KEY PLAYERS 183
FIGURE 28 R&D EXPENDITURE: MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2018 VS. 2020 183
11.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS 183
FIGURE 29 GEOGRAPHIC REVENUE ASSESSMENT: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 184
11.7 COMPANY EVALUATION QUADRANT 184
11.7.1 STARS 184
11.7.2 PERVASIVE PLAYERS 184
11.7.3 EMERGING LEADERS 185
11.7.4 PARTICIPANTS 185
FIGURE 30 LATERAL FLOW ASSAY COMPONENTS MARKET: COMPANY EVALUATION MATRIX, 2021 185
11.8 COMPETITIVE BENCHMARKING 186
11.8.1 OVERALL COMPANY FOOTPRINT 186
TABLE 184 OVERALL COMPANY FOOTPRINT (17 COMPANIES) 186
TABLE 185 COMPANY FOOTPRINT: BY TYPE (17 COMPANIES) 187
TABLE 186 COMPANY FOOTPRINT: BY REGION (17 COMPANIES) 188
11.9 COMPETITIVE SCENARIO 188
11.9.1 DEALS 189
TABLE 187 DEALS, JANUARY 2019–FEBRUARY 2022 189
11.9.2 OTHER DEVELOPMENTS 189
TABLE 188 OTHER DEVELOPMENTS, JANUARY 2019–FEBRUARY 2022 189
12 COMPANY PROFILES 190
12.1 KEY PLAYERS 190
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 DANAHER CORPORATION (PALL CORPORATION AND CYTIVA LIFE SCIENCE) 190
TABLE 189 DANAHER CORPORATION: BUSINESS OVERVIEW 190
FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 191
12.1.2 SARTORIUS STEDIM BIOTECH 195
TABLE 190 SARTORIUS STEDIM BIOTECH: BUSINESS OVERVIEW 195
12.1.3 MERCK KGAA 199
TABLE 191 MERCK KGAA: BUSINESS OVERVIEW 199
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2020) 200
12.1.4 AHLSTROM-MUNKSJÖ 204
TABLE 192 AHLSTROM-MUNKSJÖ: BUSINESS OVERVIEW 204
FIGURE 34 AHLSTROM-MUNKSJÖ: COMPANY SNAPSHOT (2020) 205
12.1.5 ADVANCED MICRODEVICES PVT. LTD. 208
TABLE 193 ADVANCED MICRODEVICES PVT. LTD.: BUSINESS OVERVIEW 208
12.1.6 DCN DIAGNOSTICS 210
TABLE 194 DCN DIAGNOSTICS: BUSINESS OVERVIEW 210
12.2 OTHER PLAYERS 211
12.2.1 FORTIS LIFE SCIENCES 211
TABLE 195 FORTIS LIFE SCIENCES: BUSINESS OVERVIEW 211
12.2.2 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD 212
TABLE 196 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD.:
BUSINESS OVERVIEW 212
12.2.3 AXIVA SICHEM BIOTECH 214
TABLE 197 AXIVA SICHEM BIOTECH: BUSINESS OVERVIEW 214
12.2.4 NUPORE FILTRATION SYSTEM 216
TABLE 198 NUPORE FILTRATION SYSTEM: BUSINESS OVERVIEW 216
12.2.5 BALLYA BIO 217
TABLE 199 BALLYA BIO: BUSINESS OVERVIEW 217
12.2.6 RUNBIO BIOTECH CO. LTD. 219
TABLE 200 RUNBIO BIOTECH CO. LTD.: BUSINESS OVERVIEW 219
12.2.7 NEENAH GESSNER 220
TABLE 201 NEENAH GESSNER: BUSINESS OVERVIEW 220
12.2.8 MAXIM BIOMEDICAL 221
TABLE 202 MAXIM BIOMEDICAL: BUSINESS OVERVIEW 221
12.2.9 CYTODIAGNOSTICS 222
TABLE 203 CYTODIAGNOSTICS: BUSINESS OVERVIEW 222
12.2.10 SENOVA GMBH 223
TABLE 204 SENOVA GMBH: BUSINESS OVERVIEW 223
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 224
13.1 DISCUSSION GUIDE 224
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 229
13.3 AVAILABLE CUSTOMIZATIONS 231
13.4 RELATED REPORTS 231
13.5 AUTHOR DETAILS 232
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.2.1 CATEGORY-WISE INCLUSIONS AND EXCLUSIONS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 33
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
FIGURE 1 LATERAL FLOW ASSAY COMPONENTS MARKET SEGMENTATION 34
1.3.2 YEARS CONSIDERED FOR THE STUDY 35
1.4 CURRENCY 35
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 35
1.5 STAKEHOLDERS 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH APPROACH 36
FIGURE 2 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 37
2.1.2 PRIMARY DATA 38
2.1.2.1 Primary sources 38
2.1.2.2 Key data from primary sources 39
2.1.2.3 Breakdown of primaries 39
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE):
BY COMPANY TYPE, DESIGNATION, AND REGION 39
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 40
2.2 MARKET SIZE ESTIMATION 40
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021) 41
FIGURE 6 SUPPLY-SIDE ANALYSIS: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 42
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 44
FIGURE 7 DATA TRIANGULATION METHODOLOGY 45
2.4 KEY INDUSTRY INSIGHTS 46
2.5 LIMITATIONS 46
2.5.1 METHODOLOGY-RELATED LIMITATIONS 46
2.6 RISK ASSESSMENT 47
2.7 ASSUMPTIONS FOR THE STUDY 47
3 EXECUTIVE SUMMARY 48
FIGURE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 48
FIGURE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2022 VS. 2027 (USD MILLION) 49
FIGURE 10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 50
FIGURE 11 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 51
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 52
4 PREMIUM INSIGHTS 53
4.1 LATERAL FLOW ASSAY COMPONENTS MARKET OVERVIEW 53
FIGURE 13 RISING NUMBER OF LOCAL MANUFACTURERS FOR COMPONENTS IS DRIVING THE GROWTH OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 53
4.2 REGIONAL MIX: LATERAL FLOW ASSAY COMPONENTS MARKET 54
FIGURE 14 APAC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 54
4.3 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE AND COUNTRY 55
FIGURE 15 MEMBRANES ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021 55
4.4 LATERAL FLOW ASSAY COMPONENTS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 56
4.5 LATERAL FLOW ASSAY COMPONENTS MARKET: DEVELOPED VS. DEVELOPING COUNTRIES 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS: IMPACT ANALYSIS 57
5.2.1 DRIVERS 58
5.2.1.1 Growing demand for lateral flow assay kits due
to the COVID-19 pandemic 58
5.2.1.2 Growing usage of home-based lateral flow assay devices 58
5.2.1.3 Growing demand for point-of-care testing 58
5.2.1.4 Increasing public-private investments to develop lateral flow assays 59
5.2.2 RESTRAINTS 59
5.2.2.1 Availability of alternative diagnostic technologies 59
5.2.3 OPPORTUNITIES 59
5.2.3.1 Evolving applications of lateral flow assays 59
5.2.4 CHALLENGES 60
5.2.4.1 Requirement of specialized storage and shipping facilities for membranes 60
5.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES (YC-YCC) IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
FIGURE 16 YC–YCC SHIFT IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 61
5.5 AVERAGE SELLING PRICE TREND 61
TABLE 2 AVERAGE SELLING PRICE OF LATERAL FLOW ASSAY COMPONENTS,
BY REGION, 2021 (USD) 61
5.6 ECOSYSTEM MARKET MAP 62
FIGURE 17 ECOSYSTEM: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 62
5.7 PATENT ANALYSIS 63
5.7.1 PATENT PUBLICATION TRENDS FOR LATERAL FLOW ASSAYS 63
FIGURE 18 GLOBAL PATENT PUBLICATION TRENDS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2016–2021 64
5.7.2 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 64
FIGURE 19 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LATERAL FLOW ASSAYS COMPONENTS, 2016–2021 64
5.8 VALUE CHAIN ANALYSIS 65
5.9 REGULATORY LANDSCAPE 66
TABLE 3 REGULATORY STANDARDS/APPROVALS REQUIRED FOR LATERAL FLOW IMMUNOASSAY PRODUCTS, BY COUNTRY/REGION 66
5.9.1 NORTH AMERICA 66
5.9.2 EUROPE 67
5.9.3 ASIA PACIFIC 67
5.9.3.1 India 67
5.9.3.2 China 67
5.9.3.3 Japan 68
5.10 TECHNOLOGY ANALYSIS 69
5.10.1 KEY TECHNOLOGY: LATERAL FLOW ASSAYS 69
5.11 KEY CONFERENCES & EVENTS DURING 2021–2023 69
TABLE 4 LATERAL FLOW ASSAY COMPONENTS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 69
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 70
5.12.1 KEY STAKEHOLDERS IN THE BUYING PROCESS 70
FIGURE 20 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
TABLE 5 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
5.12.2 BUYING CRITERIA 71
FIGURE 21 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
TABLE 6 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
5.13 PORTER’S FIVE FORCES ANALYSIS 72
TABLE 7 LATERAL FLOW ASSAY COMPONENTS MARKET:
PORTER’S FIVE FORCES ANALYSIS 72
5.13.1 THREAT FROM NEW ENTRANTS 72
5.13.2 THREAT FROM SUBSTITUTES 72
5.13.3 BARGAINING POWER OF BUYERS 73
5.13.4 BARGAINING POWER OF SUPPLIERS 73
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 73
6 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE 74
6.1 INTRODUCTION 75
TABLE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 75
6.2 MEMBRANES 75
TABLE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE,
2020–2027 (USD MILLION) 76
TABLE 10 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 76
6.2.1 NITROCELLULOSE MEMBRANES 77
6.2.1.1 Advantages of nitrocellulose membranes such as high protein-binding affinity and compatibility with a wide range of detection methods to drive market growth 77
TABLE 11 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 12 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (1 X 1 M SHEETS), BY REGION, 2020–2027 (IN THOUSANDS) 78
TABLE 13 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (20 MM X 1 M ROLLS), BY REGION, 2020–2027 (IN MILLIONS) 78
6.2.2 OTHER MEMBRANES 78
TABLE 14 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 79
6.3 PADS 80
TABLE 15 EXAMPLES OF DIFFERENT MATERIALS USED IN MANUFACTURING LATERAL FLOW ASSAY PADS 80
TABLE 16 LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 80
TABLE 17 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PADS, BY COUNTRY, 2020–2027 (USD MILLION) 81
6.3.1 SAMPLE PADS 81
6.3.1.1 Ability to promote even and controlled distribution of samples to drive market growth 81
TABLE 18 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SAMPLE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 82
6.3.2 CONJUGATE PADS 82
6.3.2.1 Conjugate pads play an important role in controlling the performance of lateral flow immunoassays 82
TABLE 19 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CONJUGATE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 83
6.3.3 ABSORBENT PADS 84
6.3.3.1 Absorbent pads prevent backflow—a key factor driving market growth 84
TABLE 20 LATERAL FLOW ASSAY COMPONENTS MARKET FOR ABSORBENT PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 84
6.4 OTHER COMPONENTS 84
TABLE 21 OTHER LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 85
7 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION 86
7.1 INTRODUCTION 87
TABLE 22 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 87
7.2 CLINICAL TESTING 87
TABLE 23 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 24 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 88
7.2.1 INFECTIOUS DISEASE TESTING 89
7.2.1.1 Rising demand for infectious disease testing in emerging markets to drive market growth 89
TABLE 25 LATERAL FLOW ASSAY COMPONENTS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 89
7.2.2 PREGNANCY & FERTILITY TESTING 90
7.2.2.1 Growing infertility levels due to changing lifestyles—a key factor driving market growth 90
TABLE 26 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PREGNANCY & FERTILITY TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 90
7.2.3 CARDIAC MARKER TESTING 91
7.2.3.1 Rising prevalence of cardiovascular diseases and growing government support to drive growth in this market segment 91
TABLE 27 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CARDIAC MARKER TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 92
7.2.4 CHOLESTEROL TESTING/LIPID PROFILING 92
7.2.4.1 Growing prevalence of obesity and CVD—
a key factor driving market growth 92
TABLE 28 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CHOLESTEROL TESTING/LIPID PROFILING, BY COUNTRY, 2020–2027 (USD MILLION) 93
7.2.5 DRUGS-OF-ABUSE TESTING 93
7.2.5.1 Technological advancements and a growing focus on workplace
drug testing are driving market growth 93
TABLE 29 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUGS-OF-ABUSE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 94
7.2.6 OTHER CLINICAL TESTING APPLICATIONS 94
TABLE 30 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER CLINICAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 95
7.3 VETERINARY DIAGNOSTICS 95
7.3.1 INFECTIOUS DISEASE OUTBREAKS (PARTICULARLY IN LARGE LIVESTOCK ANIMALS) TO DRIVE MARKET GROWTH 95
TABLE 31 LATERAL FLOW ASSAY COMPONENTS MARKET FOR VETERINARY DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 96
7.4 FOOD SAFETY & ENVIRONMENTAL TESTING 96
7.4.1 HIGH SENSITIVITY AND EASE OF USE ARE KEY FACTORS DRIVING THE DEMAND FOR LATERAL FLOW ASSAYS FOR FOOD SAFETY TESTING 96
TABLE 32 LATERAL FLOW ASSAY COMPONENTS MARKET FOR FOOD SAFETY & ENVIRONMENTAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
7.5 DRUG DEVELOPMENT & QUALITY TESTING 97
7.5.1 INCREASING FOCUS ON PRODUCT SAFETY AND QUALITY ASSURANCE TO DRIVE MARKET GROWTH IN THE COMING YEARS 97
TABLE 33 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUG DEVELOPMENT & QUALITY TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 98
8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE 99
8.1 INTRODUCTION 100
TABLE 34 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 100
8.2 SANDWICH ASSAYS 100
8.2.1 SANDWICH ASSAYS PROVIDE HIGHER LEVELS OF ASSAY SENSITIVITY AND SPECIFICITY THAN OTHER ASSAY TECHNIQUES—A KEY FACTOR DRIVING GROWTH IN THIS MARKET SEGMENT 100
TABLE 35 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SANDWICH ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 101
8.3 COMPETITIVE ASSAYS 101
8.3.1 REDUCED SELECTIVITY AND SENSITIVITY OF COMPETITIVE ASSAYS IN RELATION TO SANDWICH ASSAYS COULD HAMPER MARKET GROWTH 101
TABLE 36 LATERAL FLOW ASSAY COMPONENTS MARKET FOR COMPETITIVE ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 102
8.4 MULTIPLEX DETECTION ASSAYS 102
8.4.1 INCREASING ADOPTION OF MULTI-ANALYTE ASSAYS AMONG CLINICIANS TO DRIVE MARKET GROWTH 102
TABLE 37 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MULTIPLEX DETECTION ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION) 103
9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER 104
9.1 INTRODUCTION 105
TABLE 38 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 105
9.2 MEDICAL DEVICE MANUFACTURING COMPANIES 105
9.2.1 INCREASING USE OF POC TESTS IS DRIVING THE ADOPTION OF LATERAL FLOW ASSAY COMPONENTS AMONG MEDICAL DEVICE MANUFACTURING COMPANIES 105
TABLE 39 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE MANUFACTURING COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 106
9.3 MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES 106
9.3.1 GROWING INCLINATION TOWARD FAST AND EARLY DIAGNOSIS, ESPECIALLY IN RELATION TO THE CURRENT COVID-19 SCENARIO, WILL DRIVE MARKET GROWTH 106
TABLE 40 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES, BY COUNTRY,
2020–2027 (USD MILLION) 107
10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION 108
10.1 INTRODUCTION 109
FIGURE 22 CHINA TO REGISTER THE HIGHEST GROWTH IN THE LATERAL FLOW ASSAY COMPONENTS MARKET DURING THE FORECAST PERIOD 109
TABLE 41 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION,
2020–2027 (USD MILLION) 110
10.2 NORTH AMERICA 110
TABLE 42 NORTH AMERICA: MACROECONOMIC INDICATORS 110
FIGURE 23 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 111
TABLE 43 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 44 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 45 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 112
TABLE 46 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 113
TABLE 47 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 113
TABLE 48 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 49 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 114
TABLE 50 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 115
10.2.1 US 115
10.2.1.1 Increasing R&D investments and venture capital funding from both large and small firms towards the development of lateral flow assay diagnostics to drive market growth in the US 115
TABLE 51 US: MACROECONOMIC INDICATORS 116
TABLE 52 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 116
TABLE 53 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 116
TABLE 54 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 117
TABLE 55 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 117
TABLE 56 US: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 57 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 118
TABLE 58 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 119
10.2.2 CANADA 119
10.2.2.1 Lateral flow assay components market in Canada is estimated to grow at a relatively lower rate than the US 119
TABLE 59 CANADA: MACROECONOMIC INDICATORS 119
TABLE 60 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 120
TABLE 61 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 120
TABLE 62 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 120
TABLE 63 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 64 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 65 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 122
TABLE 66 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 122
10.3 EUROPE 122
TABLE 67 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 68 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 123
TABLE 69 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 123
TABLE 70 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 124
TABLE 71 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 124
TABLE 72 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 73 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 125
TABLE 74 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 126
10.3.1 GERMANY 126
10.3.1.1 Growing demand for POC testing to drive the lateral flow assay components market in Germany 126
TABLE 75 GERMANY: MACROECONOMIC INDICATORS 126
TABLE 76 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 127
TABLE 77 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 127
TABLE 78 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 127
TABLE 79 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 80 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 81 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 129
TABLE 82 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 129
10.3.2 FRANCE 129
10.3.2.1 High prevalence of age-related chronic diseases and infectious diseases to drive market growth in France 129
TABLE 83 FRANCE: MACROECONOMIC INDICATORS 130
TABLE 84 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 130
TABLE 85 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 130
TABLE 86 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 131
TABLE 87 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
TABLE 88 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 89 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 132
TABLE 90 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 133
10.3.3 UK 133
10.3.3.1 Severe impact of the second wave of COVID-19 in the first half of 2021 resulted in higher adoption of rapid COVID tests in the UK 133
TABLE 91 UK: MACROECONOMIC INDICATORS 134
TABLE 92 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 134
TABLE 93 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 134
TABLE 94 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 135
TABLE 95 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 135
TABLE 96 UK: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 97 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 136
TABLE 98 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 137
10.3.4 ITALY 137
10.3.4.1 Growing initiatives towards decentralization of medical services in Italy are contributing to the market growth in the country 137
TABLE 99 ITALY: MACROECONOMIC INDICATORS 137
TABLE 100 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 138
TABLE 101 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 138
TABLE 102 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 138
TABLE 103 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139
TABLE 104 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 105 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 140
TABLE 106 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 140
10.3.5 SPAIN 140
10.3.5.1 Increasing focus of international organizations and domestic players on the development of POC products in the country to drive market growth 140
TABLE 107 SPAIN: MACROECONOMIC INDICATORS 141
TABLE 108 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 141
TABLE 109 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 142
TABLE 110 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 142
TABLE 111 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 112 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 113 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 143
TABLE 114 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 144
10.3.6 REST OF EUROPE 144
TABLE 115 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 144
TABLE 116 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 145
TABLE 117 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 145
TABLE 118 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 119 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 120 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 146
TABLE 121 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 147
10.4 ASIA PACIFIC 147
FIGURE 24 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 148
TABLE 122 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 149
TABLE 123 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 149
TABLE 124 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 149
TABLE 125 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 150
TABLE 126 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 150
TABLE 127 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 128 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 151
TABLE 129 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 152
10.4.1 CHINA 152
10.4.1.1 Higher exports of lateral flow assay components during the COVID-19 pandemic to drive market growth in the country 152
TABLE 130 CHINA: MACROECONOMIC INDICATORS 153
TABLE 131 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 153
TABLE 132 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 153
TABLE 133 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 154
TABLE 134 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 154
TABLE 135 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 136 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 155
TABLE 137 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 156
10.4.2 JAPAN 156
10.4.2.1 Increasing prevalence of age-related illnesses driving the growth of the lateral flow assay components market in Japan 156
TABLE 138 JAPAN: MACROECONOMIC INDICATORS 157
TABLE 139 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 157
TABLE 140 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 157
TABLE 141 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 158
TABLE 142 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 158
TABLE 143 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 144 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 159
TABLE 145 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 160
10.4.3 INDIA 160
10.4.3.1 Increasing number of local manufacturers, growing healthcare concerns, and rising income levels to propel the growth of this market 160
TABLE 146 INDIA: MACROECONOMIC INDICATORS 160
TABLE 147 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 161
TABLE 148 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 161
TABLE 149 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 161
TABLE 150 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 162
TABLE 151 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 152 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 163
TABLE 153 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 163
10.4.4 AUSTRALIA 164
10.4.4.1 Increasing prevalence of infectious diseases, especially influenza, to drive the growth of the lateral flow assay components market in Australia 164
TABLE 154 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 164
TABLE 155 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 164
TABLE 156 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 165
TABLE 157 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 165
TABLE 158 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 159 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 166
TABLE 160 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 167
10.4.5 REST OF ASIA PACIFIC 167
TABLE 161 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 167
TABLE 162 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 168
TABLE 163 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 168
TABLE 164 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 168
TABLE 165 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 169
TABLE 166 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 169
TABLE 167 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 170
10.5 LATIN AMERICA 170
10.5.1 HIGH DEMAND FOR HIV POC DEVICES IN THE REGION TO SUPPORT THE GROWTH OF THE MARKET 170
TABLE 168 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 169 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 171
TABLE 170 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD
TYPE, 2020–2027 (USD MILLION) 171
TABLE 171 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 172
TABLE 172 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 173 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 173
TABLE 174 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 173
10.6 MIDDLE EAST & AFRICA 173
10.6.1 SIGNIFICANT SUPPORT FROM GOVERNMENTS AND GLOBAL FIRMS TOWARDS EXPANDING HEALTHCARE SERVICES DRIVES THE ADOPTION OF LATERAL FLOW ASSAYS 173
TABLE 175 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 174
TABLE 176 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 177 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 175
TABLE 178 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 175
TABLE 179 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 175
TABLE 180 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 181 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 176
TABLE 182 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 177
11 COMPETITIVE LANDSCAPE 178
11.1 OVERVIEW 178
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 178
FIGURE 25 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
11.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
FIGURE 26 REVENUE SHARE ANALYSIS FOR THE KEY PLAYERS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 180
11.4 MARKET SHARE ANALYSIS 180
FIGURE 27 LATERAL FLOW ASSAY COMPONENTS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 181
TABLE 183 LATERAL FLOW ASSAY COMPONENTS MARKET: DEGREE OF COMPETITION 182
11.5 R&D ASSESSMENT OF KEY PLAYERS 183
FIGURE 28 R&D EXPENDITURE: MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2018 VS. 2020 183
11.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS 183
FIGURE 29 GEOGRAPHIC REVENUE ASSESSMENT: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 184
11.7 COMPANY EVALUATION QUADRANT 184
11.7.1 STARS 184
11.7.2 PERVASIVE PLAYERS 184
11.7.3 EMERGING LEADERS 185
11.7.4 PARTICIPANTS 185
FIGURE 30 LATERAL FLOW ASSAY COMPONENTS MARKET: COMPANY EVALUATION MATRIX, 2021 185
11.8 COMPETITIVE BENCHMARKING 186
11.8.1 OVERALL COMPANY FOOTPRINT 186
TABLE 184 OVERALL COMPANY FOOTPRINT (17 COMPANIES) 186
TABLE 185 COMPANY FOOTPRINT: BY TYPE (17 COMPANIES) 187
TABLE 186 COMPANY FOOTPRINT: BY REGION (17 COMPANIES) 188
11.9 COMPETITIVE SCENARIO 188
11.9.1 DEALS 189
TABLE 187 DEALS, JANUARY 2019–FEBRUARY 2022 189
11.9.2 OTHER DEVELOPMENTS 189
TABLE 188 OTHER DEVELOPMENTS, JANUARY 2019–FEBRUARY 2022 189
12 COMPANY PROFILES 190
12.1 KEY PLAYERS 190
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 DANAHER CORPORATION (PALL CORPORATION AND CYTIVA LIFE SCIENCE) 190
TABLE 189 DANAHER CORPORATION: BUSINESS OVERVIEW 190
FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 191
12.1.2 SARTORIUS STEDIM BIOTECH 195
TABLE 190 SARTORIUS STEDIM BIOTECH: BUSINESS OVERVIEW 195
12.1.3 MERCK KGAA 199
TABLE 191 MERCK KGAA: BUSINESS OVERVIEW 199
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2020) 200
12.1.4 AHLSTROM-MUNKSJÖ 204
TABLE 192 AHLSTROM-MUNKSJÖ: BUSINESS OVERVIEW 204
FIGURE 34 AHLSTROM-MUNKSJÖ: COMPANY SNAPSHOT (2020) 205
12.1.5 ADVANCED MICRODEVICES PVT. LTD. 208
TABLE 193 ADVANCED MICRODEVICES PVT. LTD.: BUSINESS OVERVIEW 208
12.1.6 DCN DIAGNOSTICS 210
TABLE 194 DCN DIAGNOSTICS: BUSINESS OVERVIEW 210
12.2 OTHER PLAYERS 211
12.2.1 FORTIS LIFE SCIENCES 211
TABLE 195 FORTIS LIFE SCIENCES: BUSINESS OVERVIEW 211
12.2.2 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD 212
TABLE 196 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD.:
BUSINESS OVERVIEW 212
12.2.3 AXIVA SICHEM BIOTECH 214
TABLE 197 AXIVA SICHEM BIOTECH: BUSINESS OVERVIEW 214
12.2.4 NUPORE FILTRATION SYSTEM 216
TABLE 198 NUPORE FILTRATION SYSTEM: BUSINESS OVERVIEW 216
12.2.5 BALLYA BIO 217
TABLE 199 BALLYA BIO: BUSINESS OVERVIEW 217
12.2.6 RUNBIO BIOTECH CO. LTD. 219
TABLE 200 RUNBIO BIOTECH CO. LTD.: BUSINESS OVERVIEW 219
12.2.7 NEENAH GESSNER 220
TABLE 201 NEENAH GESSNER: BUSINESS OVERVIEW 220
12.2.8 MAXIM BIOMEDICAL 221
TABLE 202 MAXIM BIOMEDICAL: BUSINESS OVERVIEW 221
12.2.9 CYTODIAGNOSTICS 222
TABLE 203 CYTODIAGNOSTICS: BUSINESS OVERVIEW 222
12.2.10 SENOVA GMBH 223
TABLE 204 SENOVA GMBH: BUSINESS OVERVIEW 223
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 224
13.1 DISCUSSION GUIDE 224
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 229
13.3 AVAILABLE CUSTOMIZATIONS 231
13.4 RELATED REPORTS 231
13.5 AUTHOR DETAILS 232
MarketsandMarkets